期刊文献+

替格瑞洛联合尿激酶对急性ST段抬高型心肌梗死患者心肌指标及血小板聚集的影响

下载PDF
导出
摘要 目的探究替格瑞洛联合尿激酶对急性ST段抬高型心肌梗死患者心肌指标及血小板聚集的影响。方法选取医院2019年6月至2020年1月收治的80例急性ST段抬高型心肌梗死患者,根据随机双盲法分为对照组和试验组,各40例。两组均给予镇痛、吸氧等对症治疗,对照组在此基础上给予尿激酶溶栓治疗,试验组在对照组基础上加用替格瑞洛治疗,比较两组的心肌指标[肌酸激酶同工酶(CK-MB)、肌红蛋白(MYO)、超敏肌钙蛋白I(TnI-Ultra)、氨基末端脑钠肽前体(NT-proBNP)]水平、血小板聚集率及不良心血管事件发生率。结果治疗60 d后,试验组CK-MB、MYO、TnI-Ultra、NT-proBNP水平、血小板聚集率及不良心血管事件发生率均低于对照组,差异均有统计学意义(P<0.05)。结论替格瑞洛联合尿激酶能够帮助急性ST段抬高型心肌梗死患者更好地恢复心肌功能,减少血小板聚集及不良心血管事件的发生。
作者 张历
出处 《医疗装备》 2020年第13期80-81,共2页 Medical Equipment
  • 相关文献

参考文献5

二级参考文献69

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2216

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部